[ad_1] Data unveils new insights into treatment for type 2 diabetes, obesity, cardiovascular, kidney and liver diseases Cardiometabolic diseases, including cardiovascular disease, obesity, type 2 diabetes, and MASH, are increasing in prevalence in the U.S. […]
[ad_1] Cellular Therapy Emerges as a Front-Runner in Medical Innovation TAOYUAN, Oct. 20, 2024 /PRNewswire/ — Cellular therapy, a revolutionary approach where cells are manipulated outside the body and then reintroduced to treat or prevent […]
[ad_1] Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, Oct. 13, 2024 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced […]
[ad_1] First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the eight biomarkers […]
[ad_1] Advisory Committee Voted 10 to 6 in Favor, Concluding that Elamipretide is Effective for the Treatment of Barth Syndrome Elamipretide NDA Received Priority Review with a PDUFA Action Date of January 29, 2025 If Approved, Elamipretide […]
